43 completed. 43 Phase 2, 7 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 43 |
| Phase 3 | 7 | Completed 7 |
| Phase 1 | 4 | Completed 4 |
Follow Mitomycin: new trials by email Literature Review of Mitomycin trials Research Report on Mitomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture Mitomycin c - Urethral Stricture | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2022-01-01 | 2024-01-30 |
| A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C) - Urinary Bladder Neoplasms | Phase 2 | Completed | Janssen Research & Development, LLC | 107 | 2020-02-28 | 2026-02-24 |
| Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma Mitomycin c - Urothelial Carcinoma | Phase 2 | Completed | University of Florida | 29 | 2018-12-05 | 2024-11-05 |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Completed | UroGen Pharma Ltd. | 63 | 2018-10-15 | 2022-09-16 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology Surgery, Cisplatin, Mitomycin C - Gastric Adenocarcinoma, Esophagogastric Junction | Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2017-06-05 | 2025-02-19 |
| Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Mitomycin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2016-09-01 | 2024-09-19 |
| Ahmed Glaucoma Valve Surgery With Mitomycin-C Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant - Glaucoma, Primary Open Angle Glaucoma | Phase 2 | Completed | University of California, San Francisco | 119 | 2016-06-01 | 2022-05-31 |
| Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) Methotrexate, Vinblastine, Doxorubicin - Urothelial Carcinoma of the Bladder | Phase 2 | Completed | Fox Chase Cancer Center | 78 | 2016-02-24 | 2026-05-22 |
| Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life 5Fluorouracile and Mitomycin-C, Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy - Locally Advanced Anal Canal Cancer | Phase 2 | Completed | Centre Francois Baclesse | 71 | 2015-12-01 | 2026-08-31 |
| Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies Mitomycin-C, Pegfilgrastim - Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck | Phase 2 | Completed | Washington University School of Medicine | 48 | 2015-04-14 | 2025-11-18 |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients 120 mg MMC in 90ml gel, 140 mg MMC in 90ml gel, 160 mg MMC in 90ml gel - Bladder Cancer, Neoplasms | Phase 2 | Completed | UroGen Pharma Ltd. | 14 | 2014-12-01 | 2017-06-16 |
| Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer G-FLIP, G-FLIP-DM, Vitamin C - Pancreatic Cancer | Phase 2 | Completed | Bruckner Oncology | 34 | 2014-08-13 | 2024-12-11 |
| Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C Ologen, Phacotrabeculectomy, Mitomycin C - Glaucoma, Cataract | Phase 2 | Completed | Medical University of Lublin | 53 | 2014-06-02 | 2018-04-25 |
| Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer Mitomycin C, Cisplatin, Sodium Thiosulfate - Gastrointestinal Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 21 | 2014-05-08 | 2021-06-15 |
| The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device Placement of the sponge, Mitomycin-C - Primary Open Angle Glaucoma | Phase 2 | Completed | Duke University | 100 | 2014-03-01 | 2018-02-09 |
| Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma Standard Guarded Trabeculectomy, Mitomycin C, Bevacizumab - Glaucoma | Phase 2 / Phase 3 | Completed | Athens Vision Eye Institute | 40 | 2014-01-01 | 2016-09-15 |
| Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic Arm A chemotherapy, arm B chemotherapy - Adenocarcinoma of Colon, Adenocarcinoma of Rectum | Phase 2 | Completed | Centro Nacional de Investigaciones Oncologicas CARLOS III | 29 | 2012-11-01 | 2015-10-09 |
| HIPEC for Peritoneal Carcinomatosis HIPEC, Mitomycin C - Peritoneal Carcinomatosis, Colorectal Cancer | Phase 2 | Completed | Albert Einstein College of Medicine | 51 | 2011-11-01 | 2024-10-24 |
| Second Line Therapy in Advanced Biliary Tract Cancer capecitabine and mitomycin, Capecitabine - Biliary Tract Cancer | Phase 2 | Completed | IRCCS San Raffaele | 52 | 2011-11-01 | 2016-02-25 |
Showing 20 of 43. Sign in to see all of them.
Urinary Bladder Neoplasms (7) · Glaucoma (6) · Non-Muscle Invasive Bladder Neoplasms (6) · Neoplasm Metastasis (5) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Liver Neoplasms (3) · Stomach Neoplasms (3) · Appendiceal Neoplasms (2) · Carcinoma, Transitional Cell (2) · Gastrointestinal Neoplasms (2) · Glaucoma, Open-Angle (2) · Pancreatic Neoplasms (2) · Peritoneal Neoplasms (2) · Adenocarcinoma (1)
M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Radiation Therapy Oncology Group (2) · UroGen Pharma Ltd. (2) · Ain Shams University (1) · Albert Einstein College of Medicine (1) · Athens Vision Eye Institute (1) · Australasian Gastro-Intestinal Trials Group (1) · Bruckner Oncology (1) · Centre Francois Baclesse (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · Duke University (1) · Eastern Cooperative Oncology Group (1) · Eli Lilly and Company (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
United States (25) · Italy (4) · India (3) · Israel (3) · Australia (2) · Belgium (2) · China (2) · France (2) · Japan (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Canada (1) · Czechia (1)
Aldo V. Bono, MD (1) · Azriel Hirschfeld, MD (1) · Brian D Badgwell (1) · Brian D. Badgwell, MD (1) · Carsten Bokemeyer, MD (1) · Edward Levine (1) · Elyse Seltzer, MD (1) · Gerassimos Kopsinis, M.D., Ph.D. (1) · Harubumi Kato, M.D., Ph.D. (1) · Ifat Klein, PhD (1)
PMID 34125951, PMID 41074972, PMID 17470859, PMID 20354452, PMID 20570237, PMID 21156335, PMID 24362862, PMID 25019269, PMID 25954110, PMID 27519353, PMID 28643069, PMID 29189540, PMID 30247524, PMID 32556731, PMID 33660142, PMID 34433303, PMID 35640276, PMID 39226514, PMID 39680823
2019 (1), 2023 (1), P30CA015083 (1), U10CA021115 (1), U10CA032102 (1)